

**2024 Financial Conflict of Interest Annual Collection  
TRIALS LISTING WITH RELEVANT COMPANY/COMMERCIAL ENTITY  
All Trials Not Permanently Closed (as of 28 February 2024)**

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/Commercial entity
<b>BRAIN</b>					
CE7	A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases	Open	CCTG-Led	Yes	No commercial entity
CE9	Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)	Planned	IG Led	No	No commercial entity
CEC2	Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma	Closed	IG Led	Yes	Merck, Schering
CEC6	Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma	Open	IG Led	Yes	Merck, Schering
CEC7	Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease	Closed	IG Led	Yes	No commercial entity
<b>BREAST</b>					
MA32D	Change In Mammographic Density with Metformin Use: A Companion Study to NCIC CTG Study MA.32	Closed	IG Led	Yes	No commercial entity
MA34	A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer	Closed	IG Led	No	Hoffmann-La Roche Limited
MA39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Node Positive Luminal A Breast Cancer	Open	CCTG-Led	Yes	No commercial entity
MA40	A Double Blind Placebo Controlled Randomized Phase III Trial of Ipatasertib in Combination with Fulvestrant as Immediate Treatment for Metastatic Estrogen Receptor Positive (ER+) and HER-2 Negative Breast Cancer post CDK4/6 Inhibitor and Aromatase Inhibitor	Open	CCTG-Led	No	Roche
MA41	De-Escalation of adjuvant Chemotherapy in HER-2 positive, Estrogen receptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blockade (DECRESFENDO)	Closed	IG Led	No	No commercial entity
MAC19	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy	Closed	IG Led	Yes	No commercial entity
MAC20	Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	Closed	IG Led	Yes	Nestle
MAC21	Aspirin for Breast Cancer (ABC): Randomized Trial of Aspirin as Adjuvant Therapy for Node Positive Breast Cancer	Closed	IG Led	Yes	Bayer
MAC22	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	Open	IG Led	Yes	No commercial entity
MAC23	Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction	Closed	IG Led	No	No commercial entity
MAC24	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with $\geq 1$ cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy	Closed	IG Led	Yes	Merck
MAC25	Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Cancer	Closed	IG Led	Yes	Eli Lilly
MAC26	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer	Open	IG Led	Yes	AstraZeneca
MAC27	COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib	Open	IG Led	Yes	Seattle Genetics
MAC28	A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score $\leq 18$ Breast Cancer (DEBRA)	Open	IG Led	Yes	No commercial entity
MAC29	OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy	Planned	IG Led	Yes	No commercial entity
<b>GASTROINTESTINAL</b>					
CO21	A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE).	Open	CCTG-Led	No	No commercial entity

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
CO27	Irinotecan and Oxaliplatin for Colon cancer in the Adjuvant Setting: mFOLFIRINOX triplet chemotherapy for high-risk stage III colon cancer in adjuvant setting (IROCAS study): A Phase III Randomised Trial	Closed	IG Led	No	No commercial entity
CO29	Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC III)	Closed	IG Led	No	No commercial entity
CO32	The NEO-RT Trial: Randomized Trial of Neoadjuvant Chemotherapy, Excision, and Observation with or without Selective ChemoRadioTherapy for Early Rectal Cancer.	Planned	CCTG-Led	Yes	No commercial entity
CRC3	A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers	Closed	IG Led	Yes	Sanofi-Aventis; Hoffmann-La Roche/Genentech
CRC7	A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally	Closed	IG Led	Yes	No commercial entity
CRC8	A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High-Risk Anal Cancer	Closed	IG Led	Yes	Nivo, BMS
CRC9	Phase II/III Study of Circulating Tumor DNA as a Predictive Marker for Response to Adjuvant Chemotherapy in Patients with Stage II Colon Cancer	Hold	IG Led	Yes	No commercial entity
CRC10	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)	Open	IG Led	Yes	No commercial entity
ES3	NEEDS: NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed)	Planned	CCTG-Led	No	No commercial entity
GA1	A Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer (TOPGEAR)	Closed	IG Led	No	Novartis
GA3	A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Closed	IG Led	No	Bayer Healthcare Pharmaceuticals
GA4	A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma	Open	CCTG-Led	No	Jazz Pharmaceuticals
HE1	Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases	Closed	CCTG-Led	No	No commercial entity
NE1	NET RETREAT: A Phase II Study of 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET	Open	CCTG-Led	Yes	Novartis
NE2	STOPNET - A Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Med-Gut Neuroendocrine Tumours	Planned	AGITG	No	No commercial entity
NEC3	Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors	Closed	IG Led	Yes	Novartis
PAC3	Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Open	IG Led	Yes	No commercial entity
PAC4	Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs	Open	IG Led	Yes	No commercial entity
<b>GENITOURINARY</b>					
BL13	A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer	Closed	CCTG-Led	No	AstraZeneca
BL13F	Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-Study of BL13 e-PRISM	Closed	CCTG-Led	No	AstraZeneca, uMotif
BLC1	A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer	Closed	IG Led	Yes	No commercial entity
BLC5	MAIN-CAV: Phase III Randomized Trials of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Patients with Metastatic Urothelial Cancer	Open	IG Led	Yes	No commercial entity
GCC1	A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours	Open	IG Led	Yes	No commercial entity
PR19	A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer	Open	CCTG-Led	No	No commercial entity
PR20	A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]	Open	CCTG-Led	No	TerSera Therapeutics LLC
PR21	PLUDO (Prostate Lutetium/Docetaxel): A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease	Closed	CCTG-Led	No	EndoCyte and/or Novartis
PR22	DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer	Closed	IG Led	No	Bayer
PR24	Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)	Planned	CCTG-Led	Yes	No commercial entity

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
PR25	A Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes	Planned	CCTG-Led	No	No commercial entity
PR26	TRIPLE-SWITCH: A Randomized Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer Without Deep PSA Response	Planned	CCTG-Led	No	No commercial entity
REC4	A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	Closed	IG Led	Yes	BMS
<b>GYNECOLOGY</b>					
CX5	A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer (SHAPE)	Closed	CCTG-Led	No	No commercial entity
CX6	International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III	Open	IG Led	No	No commercial entity
CXC2	A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	Closed	IG Led	Yes	Nanopharmaceuticals, Inc.
EN10	Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma	Open	CCTG-Led	No	No commercial entity
EN11	RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial	Open	IG Led	No	AstraZeneca
OV25	A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer with BRCA 1 and 2 Mutations (STICs and STONES)	Closed	CCTG-Led	No	Apotex Inc.
OV26	An International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Patients with Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy	Closed	IG Led	No	AstraZeneca
OVC2	A Randomized Phase II/III study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	Closed	IG Led	Yes	AstraZeneca
VU2	STRatification of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study	Planned	CCTG-Led	No	No commercial entity
<b>HEAD AND NECK</b>					
HN9	Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)	Closed	CCTG-Led	No	AstraZeneca
HN10	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma	Closed	CCTG-Led	No	No commercial entity
HN11	SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT): A Phase III Randomized Controlled Trial	Open	CCTG-Led	Yes	No commercial entity
HN13	Optimizing Head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: A Phase III Trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)	Planned	CCTG-Led	No	No commercial entity
HNC2	Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	Closed	IG Led	Yes	Durva, AstraZeneca
<b>HEMATOLOGY</b>					
AL5	Dana Farber Cancer Institue (DFCI) Acute Lymphoblastic Leukemia (ALL) Adult Consortium Trial: Adult ALL Trial	Closed	IG Led	Yes	Sigma Tau (Baxter), Novartis
AL6	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with AML	Planned	CCTG-Led	No	No commercial entity
ALC4	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.	Closed	IG Led	Yes	Amgen
ALC6	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL	Hold	IG Led	No	Pfizer
ALC7	Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials	Planned	IG Led	Yes	MDNet

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
ALC8	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH Clinical Trial	Planned	IG Led	Yes	AbbVie
ALC9	Eradicating Minimal Residual Disease in patients with AML prior to Stem Cell Transplant (ERASE): A MyeloMATCH Treatment Trial	Planned	IG Led	Yes	AbbVie
CLC2E	A Prospective Economic Analysis of NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= 65 Years of Age) With Chronic Lymphocytic Leukemia	Closed	CCTG-Led	No	Janssen Inc.
CLC.3	Randomized Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study	Open	IG Led		AbbVie, Roche
CLC3E	An Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Companion Analysis to CCTG CLC.3/SWOG 1925 Randomized Phase III Clinical Trial	Open	CCTG-Led	No	No commercial entity
HD11	A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma	Open	CCTG-Led	No	Merck, Seattle Genetics
HD12	A Randomized Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Previously Treated Stage IA/IIA Hodgkin Lymphoma (RADAR)	Open	IG Led	No	Seattle Genetics
HDC1	A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma	Closed	IG Led	Yes	Seattle Genetics
LY17	A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma	Open	CCTG-Led	No	Janssen Inc.
LY18	A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	Open	CCTG-Led	No	AbbVie, Roche, Incyte
LYC1	Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV -> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)	Closed	IG Led	Yes	Lundbeck Canada Inc. Teva Oncology
MY13	A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma	Open	CCTG-Led	No	No commercial entity
MYC2	Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)	Open	IG Led	Yes	No commercial entity
<b>INVESTIGATIONAL NEW DRUG</b>					
I206	A Phase II Study of Sunitinib or Temozolimide in Patients with Advanced Rare Tumours	Closed	CCTG-Led	No	Pfizer Canada Inc.
I214	A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours	Closed	CCTG-Led	No	OHRI, Turnstone
I223	A Phase II Study of Ribociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer	Closed	CCTG-Led	No	Novartis
I228	A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours	Closed	CCTG-Led	No	AstraZeneca
I232	A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer	Closed	CCTG-Led	No	AstraZeneca
I234	Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol	Closed	CCTG-Led	No	AstraZeneca, Bayer
I234A	A Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234	Closed	CCTG-Led	No	AstraZeneca
I234B	A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234	Closed	CCTG-Led	No	AstraZeneca
I234C	A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234	Closed	CCTG-Led	No	Bayer
I234D	A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Closed	CCTG-Led	No	No commercial entity

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
I234E	A Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)	Closed	CCTG-Led	No	Roche
I234F	A Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate Cancer	Closed	CCTG-Led	No	AstraZeneca
I234G	A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer	Closed	CCTG-Led	No	No commercial entity
I236	A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer	Closed	CCTG-Led	No	UHN
I237	A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer	Closed	CCTG-Led	No	UHN
I238	A Phase II Study of Durvalumab Retreatment in Patient who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity	Open	CCTG-Led	No	AstraZeneca
I238B	A Phase II Study of Durvalumab Substudy B: For Continued Treatment (+/-) Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	Open	CCTG-Led	No	AstraZeneca
I239	A Multicenter Phase Ib/II Study of a Polo-Kinase 4 Inhibitor CFI-400945 + the PD-L1 Inhibitor Durvalumab in Patients with Triple Negative Breast Cancer (TNBC)	Closed	CCTG-Led	No	AstraZeneca
I240	An Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC)	Open	CCTG-Led	No	AstraZeneca, BioAtla
I240A	A Phase II Study of Durvalumab and BA3011, A CAB-AXL-ADC in Patients with Platinum Resistant High Grade Serous Ovarian Cancer	Open	CCTG-Led	No	AstraZeneca, BioAtla
I240B	A Phase II Study of Durvalumab and BA3021, A CAB-ROR2-ADC in Patients with Platinum Resistant High Grade Serous Ovarian Cancer	Open	CCTG-Led	No	AstraZeneca, BioAtla
I241	A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer	Open	CCTG-Led	No	No commercial entity
I241A	Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment	Open	CCTG-Led	No	Tempus, EPIC
I241B	A Phase II Study of RP-6306 in Patients with CDK4/6-Inhibitor Treated ER+HER2-Metastatic Breast Cancer Receiving Gemcitabine	Open	CCTG-Led	No	Repare Therapeutics, Tempus, EPIC
I241C	A Phase II Study of Niraparib, A PARP Inhibitor, in Patients with CDK4/6-Inhibitor Treated ER+/HER2- Metastatic Breast Cancer	Open	CCTG-Led	No	GlaxoSmithKline, Tempus, EPIC
I242	Neoadjuvant Platform Trial in Patients with Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)	Open	CCTG-Led	No	No commercial entity
I242A	A Phase II Pre-operative Trial of JDQ433 in Patients with Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)	Open	CCTG-Led	No	Novartis
I243	A Phase II Study of RP-6306 in Patients with Advanced Cancer	Open	CCTG-Led	No	Repare Therapeutics
I244	A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary Central Nervous System Lymphoma	Open	CCTG-Led	No	Janssen Inc.
<b>LUNG</b>					
BR31	A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer	Closed	CCTG-Led	No	AstraZeneca, MedImmune
BR36	A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer	Closed	CCTG-Led	No	PGDx
BR37	A Randomized Phase II /III Trial of Tusamitamab Ravtansine (Tusa) versus Investigator Choice in Patients with CEACAM5 Positive Non-Small Cell Lung Cancer After the Failure of Standard of Care Systemic Therapy	Planned	CCTG-Led	No	Sanofi-Aventis
BRC2E	A Prospective Economic Analysis of NCIC CTG BRC.2/E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Closed	CCTG-Led	No	Roche/Genentech
BRC6	Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer	Closed	IG Led	Yes	MedImmune (AstraZeneca), Genentech, Pfizer, AstraZeneca, BMS
BRC6B	A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	Genentech (Roche)
BRC6C	A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	Pfizer
BRC6D	A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	AstraZeneca
BRC6F	A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)	Closed	IG Led	No	AstraZeneca
BRC6G	A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	Medivation

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/Commercial entity
BRC6I	A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)	Closed	IG Led	No	BMS
BRC7	EA5163/S1709 INSIGNA: A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis	Open	IG Led	Yes	No commercial entity
BRC8	A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation in Small-Cell Lung Cancer	Open	IG Led	Yes	No commercial entity
<b>MELANOMA</b>					
ME13	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)	Open	CCTG-Led	No	No commercial entity
ME13L	A Biomarker Sub-study of the CCTG ME.13 Duration of Anti PD-1 Therapy in Metastatic Melanoma STOP-GAP Trial	Open	CCTG-Led	No	No commercial entity
ME15	Melanoma Margins Trial II - A Phase III, Multi-centre Randomized Controlled Trial Investigating 1cm vs 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II)	Open	IG Led	No	No commercial entity
ME17	Phase II Randomized Trial of Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade Compared to Immune Checkpoint Blockade Alone in Patients with Advanced Melanoma	Planned	CCTG-Led	No	No commercial entity
MEC6	A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma	Open	IG Led	Yes	Exelixis, BristolMyersSquibb
<b>SARCOMA</b>					
SR7	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)	Open	IG Led	No	No commercial entity
<b>SUPPORTIVE CARE</b>					
SC26	Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia	Open	CCTG-Led	No	No commercial entity
SC27	Living with Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors	Closed	CCTG-Led	No	No commercial entity
SC28	The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfulnEss intervention for cancer SurvivorS	Open	CCTG-Led	No	No commercial entity
SC29	A Randomized Phase 3 Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases	Planned	CCTG-Led	No	No commercial entity
SC30	Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematology Platform Trial - RATIONAL-PT	Planned	AUMO	No	No commercial entity
IC8	COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure	Closed	CCTG-Led	No	Immodulon
ICC1	NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study	Closed	IG Led	Yes	No commercial entity
<b>PRECISION MEDICINE</b>					
PM1	Canadian Profiling and Targeted agent Utilization tRial (CAPTUR)	Open	CCTG-Led	No	BMS, Roche, Pfizer, AstraZeneca, Seattle Genetics
PM1S	Insight of the Use and Value of Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients	Closed	CCTG-Led	No	Roche